Arshad, Shanze
Fang, Xi http://orcid.org/0000-0002-6692-5730
Ahn, Kwang W.
Kaur, Manmeet
Scordo, Michael
Sauter, Craig S.
Furqan, Fateeha
Awan, Farrukh T.
Hamadani, Mehdi http://orcid.org/0000-0001-5372-510X
Article History
Received: 2 May 2023
Revised: 29 June 2023
Accepted: 17 July 2023
First Online: 10 August 2023
Competing interests
: MH reports Consultancy: Incyte Corporation, MorphoSys, SeaGen, Gamida Cell, Novartis, Legend Biotech, Kadmon, ADC Therapeutics; Omeros, CRISPR, Genmab, Kite, BMS, Caribou, Abbvie. Speaker’s Bureau: Sanofi Genzyme, AstraZeneca, BeiGene, ADC Therapeutics, Kite. DMC: Myeloid Therapeutics, Inc, Genentech. MS served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., and Omeros Corporation; served on ad hoc advisory boards for Kite—A Gilead Company; and received honoraria from i3Health and Medscape for CME-related activity. CSS has served as a paid consultant: Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK. He has received research funds for clinical trials from: Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA. FTA has provided consultancy to: Genentech, Astrazeneca, Abbvie, Janssen, Pharmacyclics, Gilead sciences, Kite pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme, Caribou Biosciences, Cellecter Bisosciences, Loxo Oncology, Adaptive Biotechnologies, and received research funding from Pharmacyclics.